PRMT9
Protein arginine N-methyltransferase 9
Also known as: ANM9_HUMAN, FLJ46629, PRMT10
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6P2P2
- Gene
- PRMT9
- Ensembl
- ENSG00000164169
- Chromosome
- 4
- Canonical length
- 845 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Microtubules,Cytosol
OverviewNCBI Gene
This gene encodes a type II methyltransferase. Post-translational modification of target proteins by PRMTs plays an important regulatory role in many biological processes, whereby PRMTs methylate arginine residues by transferring methyl groups from S-adenosyl-L-methionine to the guanidino nitrogen atoms of arginine. The protein encoded by this gene methylates spliceosome associated protein 145 to regulate alternative splicing and acts as a modulator of small nuclear ribonucleoprotein maturation. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Apr 2017]
Canonical amino-acid sequenceUniProt
845 residues, UniProt reviewed canonical sequence.
>Q6P2P2|PRMT9
1 MSNSRPRSRR DAGGGAGAAG RDELVSRSLQ SAEHCLGVQD FGTAYAHYLL VLSLAPELKH
61 DVKETFQYTL FRWAEELDAL SRIQDLLGCY EQALELFPDD EVICNSMGEH LFRMGFRDEA
121 AGYFHKAVKL NPDFSDAKEN FYRVANWLVE RWHFIMLNDT KRNTIYNAAI QKAVCLGSKS
181 VLDIGAGTGI LSMFAKKAGA HSVYACELSK TMYELACDVV AANKMEAGIK LLHTKSLDIE
241 IPKHIPERVS LVVTETVDAG LFGEGIVESL IHAWEHLLLQ PKTKGESANC EKYGKVIPAS
301 AVIFGMAVEC AEIRRHHRVG IKDIAGIHLP TNVKFQSPAY SSVDTEETIE PYTTEKMSRV
361 PGGYLALTEC FEIMTVDFNN LQELKSLATK KPDKIGIPVI KEGILDAIMV WFVLQLDDEH
421 SLSTSPSEET CWEQAVYPVQ DLADYWIKPG DHVMMEVSCQ DCYLRIQSIS VLGLECEMDV
481 AKSFTQNKDL LSLGNEAELC SALANLQTSK PDAVEQTCIL ESTEIALLNN IPYHEGFKMA
541 MSKVLSSLTP EKLYQTMDTH CQNEMSSGTG QSNTVQNILE PFYVLDVSEG FSVLPVIAGT
601 LGQVKPYSSV EKDQHRIALD LISEANHFPK ETLEFWLRHV EDESAMLQRP KSDKLWSIII
661 LDVIEPSGLI QQEIMEKAAI SRCLLQSGGK IFPQYVLMFG LLVESQTLLE ENAVQGTERT
721 LGLNIAPFIN QFQVPIRVFL DLSSLPCIPL SKPVELLRLD LMTPYLNTSN REVKVYVCKS
781 GRLTAIPFWY HMYLDEEIRL DTSSEASHWK QAAVVLDNPI QVEMGEELVL SIQHHKSNVS
841 ITVKQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PRMT9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 11 nTPM
Expression across tissuesHPA
Tissue
- ovary: 11 nTPM
- adrenal gland: 9.3 nTPM
- bone marrow: 8 nTPM
- testis: 6.7 nTPM
- parathyroid gland: 5.8 nTPM
- thyroid gland: 5.4 nTPM
Single-cell type
- innate lymphoid cells: 438 nCPM
- pdcs: 346 nCPM
- ovarian stromal cells: 261 nCPM
- somatotrophs: 249 nCPM
- lactotrophs: 209 nCPM
- monocytes: 204 nCPM
Immune cell
- eosinophil: 8.6 nTPM
- memory B-cell: 7.5 nTPM
- naive B-cell: 7.2 nTPM
- naive CD4 T-cell: 7.1 nTPM
- naive CD8 T-cell: 6.2 nTPM
- basophil: 6.1 nTPM
Brain region
- cerebellum: 8.3 nTPM
- cerebral cortex: 6.9 nTPM
- hippocampal formation: 6 nTPM
- choroid plexus: 5.9 nTPM
- hypothalamus: 5.6 nTPM
- spinal cord: 5.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PRMT9.
Disease | GeneticClinVar
18 pathogenic / likely-pathogenic of 137 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Neurodevelopmental abnormality
- PRMT9-associated neurodevelopmental disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.93
- gnomAD pLI
- 0
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- histone methyltransferase activity
- protein-arginine N-methyltransferase activity
- protein-arginine omega-N symmetric methyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Tetratricopeptide-like helical domain superfamily
- Tetratricopeptide repeat
- Protein arginine N-methyltransferase
- S-adenosyl-L-methionine-dependent methyltransferase superfamily
- Protein arginine N-methyltransferase domain
- Ribosomal protein L11 methyltransferase (PrmA)
- Arginine methyltransferase oligomerization subdomain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PRMT9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PRMT9 as an antibody target. Whether an autoantibody or antibody against PRMT9 could matter depends on whether native PRMT9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PRMT9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PRMT9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...